Physician profile
Robert E Toner
NPI 1720077894
$2,261.96
in general payments reported to CMS, 2019-2025
30 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $976 · 2022: $895 · 2023: $44.30 · 2024: $178 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $298.45 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Actelion Pharmaceuticals US, INC. | $245.03 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.83 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $193.94 | 2021-2022 | |
| Chiesi USA, INC. | $152.06 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $150.71 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $142.55 | 2021-2022 | |
| Insmed, INC. | $109.11 | 2021-2022 | |
| Grifols USA, LLC | $98.89 | 2021-2022 | |
| Electromed, INC. | $96.38 | 2021-2025 | Smartvest |
| Mylan Specialty L.P. | $57.69 | 2022-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $45.45 | 2021 | |
| Kaleo, INC. | $42.99 | 2021-2022 | |
| Pfizer INC. | $41.31 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $37.21 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $32.32 | 2021 | |
| Genzyme Corporation | $31.91 | 2024 | |
| Gilead Sciences, INC. | $31.03 | 2021 | |
| Astellas Pharma US INC | $27.60 | 2024-2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $21.81 | 2024 | Dupixent |
| Axsome Therapeutics, INC. | $21.41 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $19.72 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.86 | 2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $17.51 | 2024 | Voquezna |
| Viatris Specialty LLC | $16.81 | 2025 | Yupelri |
| Lilly USA, LLC | $16.62 | 2025 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $15.59 | 2023 | |
| Novo Nordisk INC | $15.10 | 2023 | Rybelsus |
| Genentech USA, INC. | $14.01 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Toner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.